Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q02747
UPID:
GUC2A_HUMAN
Alternative names:
Guanylate cyclase activator 2A; Guanylate cyclase-activating protein 1; Guanylate cyclase-activating protein I
Alternative UPACC:
Q02747
Background:
Guanylin, officially known as Guanylate cyclase activator 2A, plays a pivotal role in the regulation of electrolyte and water transport in intestinal cells. It activates intestinal guanylate cyclase through a mechanism similar to that of heat-stable enterotoxins, highlighting its critical function in maintaining fluid balance and preventing dehydration.
Therapeutic significance:
Understanding the role of Guanylin could open doors to potential therapeutic strategies. Its unique mechanism of stimulating guanylate cyclase presents an opportunity for developing treatments aimed at disorders related to electrolyte imbalance and intestinal fluid transport.